A new sensor from QLD-based company, WearOptimo, could provide medical professionals with a tool to forecast which COVID-19 patients are on the path to severe respiratory distress allowing earlier, more appropriate treatment.
The company’s device monitors the reaction of the body’s immune system to the disease. It measures levels of a protein called IL-6, an inflammatory cytokine that is produced to help tackle infection but can cause damage to organs and tissue when the body produces too much of it.
